Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00719212 · ClinicalTrials.gov registry record · Phase 2
Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer
A Phase 2 study of Ovarian Neoplasms, sponsored by Translational Research in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
- 20
- Study locations
NCT00719212: Completed Phase 2 study of Ovarian Neoplasms, sponsored by Translational Research in Oncology.
NCT00719212 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Translational Research in Oncology. The registered enrollment target is 61 participants, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00719212, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Translational Research in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
Primary Outcome
RECIST(v1.0):CR:disappearance of all target lesions or disappearance of all nontarget lesions \& normalization of tumor marker level/•PR:at least 30% decrease in the sum of the longest diam(LD) of target les° taking as ref the baseline sum LD OR CR for target les° \& incomplete response/SD for nontarget les°. CR \& PR to be confirmed no less than 4 wks after initial doc of response.The def of the resp acc to serum CA125 level was as per GCIGCA125 criteria: * PR:elevated CA125 at baseline PR co
Conditions Studied
Interventions
- BIOLOGICAL AMG 479
Study Locations (20)
California
- Comprehensive Blood and Cancer Center - Bakersfield
- St Jude Heritage Healthcare - Fullerton
- Wilshire Oncology Medical Group Inc - La Verne
- LAC/USC Medical Center - Los Angeles
- University of Southern California/ Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- UCLA - Los Angeles
- North Valley Hematology/ Oncology Medical Group - Northridge
- Ventura County Hematology Oncology Specialists - Oxnard
- Central Hematology Oncology Medical Group Inc. - Pasadena
Other
- Tom Baker Centre - Calgary
- Juravinski Cancer Center - Hamilton
- CHUM Hôpital Notre Dama - Montreal
- Jewish General Hospital - Montreal
Colorado
- University of Colorado - Aurora
Illinois
- University of Chicago - Chicago
Kansas
- Cancer Center of Kansas - Wichita
Michigan
- St Joseph Mercy Health System - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
Nevada
- Comprehensive Cancer Centre of Nevada - Henderson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
What the finished NCT00719212 record still lists
NCT00719212 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 366-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which AMG 479 is the first listed.
NCT00719212 names 20 study sites across 8 states, led by California, Other, Colorado.
Frequently Asked Questions
What is clinical trial NCT00719212 about?
NCT00719212 is a clinical study titled "Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer". The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
What is the current status of trial NCT00719212?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-01. Estimated completion is 2013-05.
What conditions does trial NCT00719212 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
What interventions are being tested in trial NCT00719212?
The interventions under investigation include: AMG 479 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00719212?
This trial is sponsored by Translational Research in Oncology, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00719212 being conducted?
This trial has 20 study locations across California, Colorado, Illinois, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00719212's enrollment target sits among peer trials
61 30th of 38 higher than 9 of 38 other Ovarian Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04115306 · 61 participants · Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
- NCT05070845 · 61 participants · Phase 2
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
- NCT05187832 · 61 participants · Phase 1
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
- NCT05269316 · 61 participants · Phase 1
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia